WO1999062554A1 - Preparations de prevention / de traitement de maladies demyelinisantes auto-immunes - Google Patents
Preparations de prevention / de traitement de maladies demyelinisantes auto-immunes Download PDFInfo
- Publication number
- WO1999062554A1 WO1999062554A1 PCT/JP1999/002818 JP9902818W WO9962554A1 WO 1999062554 A1 WO1999062554 A1 WO 1999062554A1 JP 9902818 W JP9902818 W JP 9902818W WO 9962554 A1 WO9962554 A1 WO 9962554A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fas
- apoptosis
- substance
- antibody
- ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to a preventive / therapeutic agent for an autoimmune demyelinating disease, which comprises a substance that suppresses apoptosis as an active ingredient.
- Fas is a monoclonal antibody obtained by immunizing a mouse with human fibroblasts.
- the Fas antibody (Yonehara S. et al., J. Ep. Med., 169, 1747—1756, 1989 And is a cell surface antigen that transmits apoptotic signals to cells. According to Itoh N. et al., The Fas gene was cloned, and it was found that Fas is a protein on the cell membrane of about 45 kD and its amino acid sequence belongs to the TNF receptor Yuichi family (Cel 66, 233-243, 1991).
- mouse Fas gene was also cloned, and it was confirmed that Fas mRNA was expressed in the mouse thymus, liver, lung, heart, and ovary (Watanabe — Fukunaga, etc. J. Immunol., 148, 1274-1279, 1992).
- Human Fas ligand is a polypeptide reported by Nagata et al. As an in vivo molecule that induces apoptosis in cells expressing Fas. (Takahashi T. et al., International Immunology, Vol. 6, pp. 157-157, pp. 1974, 1994). Human Fas ligand is a type II glycoprotein with a molecular weight of about 40 kD belonging to the TNF family, and is considered to form a trimer in vivo, like TNF (Tanaka M. et al., EMB ⁇ J ourna, Vol. 14, 1 129–1 135, 1995). Human Fas ligands include rat Fas ligands (Suda T.
- Human Fas ligand recognizes not only human Fas but also mouse Fas and induces apoptosis. be able to. Conversely, rat Fas ligand and mouse Fas ligand can also recognize human Fas and induce apo! ⁇ Cis.
- Fas-mediated apo-cis signal transduction Studies on the mechanism of intracellular signaling of apoptosis via Fas have been advanced, and it interacts with the intracellular domain of Fas, especially the domain called death domain (Death doma in) to transmit or transmit signals. Identification and cloning of suppressors have been reported, suggesting that interleukin-11-converting enzyme (ICE) -related thiol protease may contribute to Fas-mediated apo-cis signal transduction. Have been.
- ICE interleukin-11-converting enzyme
- apoptosis especially Fas-mediated apoptosis
- Fas-mediated apoptosis is associated with various diseases and physiological phenomena.
- apoptosis especially Fas-mediated apoptosis
- hepatic cell death in viral fulminant hepatitis and certain autoimmune diseases abnormalities of Fas-mediated apoptosis Possible involvement has been suggested.
- FasZF as ligand system may be responsible for functions other than apoptosis, for example, neutrophils and inflammatory effects (Kayagaki N. et al. 28, 667-675, 1996).
- An autoimmune disease is a disease caused by autoreactive lymphocytes reacting and attacking a self-antigen, and has various symptoms. Under normal conditions, a living body does not show an excessive immune response to self-antigens, and thus self-tolerance is established.However, if the immune regulation function is abnormal, antibodies are produced against its own components or self-reaction occurs. Sexual lymphocytes appear. These self-reactive T cells are originally eliminated by apoptosis in the thymus, but accumulate there when they migrate to the periphery without being eliminated by some abnormality.
- Autoimmune demyelinating disease is a disease caused by autoantibodies specific to the nervous system and caused by selective damage to the myelin sheath and its forming cells. Histologically, there is loss of myelin and cell infiltration around the vein. Clinical symptoms include neurological symptoms such as blindness, sensory disturbance, and paralysis of the extremities.
- demyelinating inflammation such as multiple sclerosis that recurs and recurs may involve autoimmunity (De Keyser J , N eurology, 3 8 3 p. 74, 1988), as well as viral infection (Carp R. I. et al., Prog. Med. Viol., 24, 158-177, 1978). ing.
- An object of the present invention is to provide a prophylactic / therapeutic agent for a self-immune demyelinating disease by a novel mechanism of action that suppresses apoptosis. More specifically, the present invention provides a prophylactic / therapeutic agent and a method for treating an autoimmune demyelinating disease comprising a substance that inhibits apoptosis as an active ingredient.
- the present inventors have intensively studied the relationship between apoptosis and the disease in order to rescue patients with autoimmune demyelinating disease, but the substance that suppresses apoptosis in an autoimmune demyelinating disease model has been studied. And found that the present invention was completed.
- the present invention relates to the following prophylactic and therapeutic agents.
- a prophylactic / therapeutic agent for autoimmune demyelinating disease containing a substance that suppresses apoptosis as an active ingredient.
- autoimmune demyelinating disease is a disease in which demyelination occurs in the central nervous system.
- autoimmune demyelinating disease is at least one selected from the group consisting of acute sporadic encephalomyelitis and multiple sclerosis. Therapeutic agent.
- a method for preventing and treating an autoimmune demyelinating disease by administering a substance that suppresses apoptosis by administering a substance that suppresses apoptosis.
- FIG. 1 is a graph showing the effect of FLIM58 on improving the disease state in a rat EAE model.
- Figure 2 shows the effect of FLIM58 on improving weight loss in a rat EAE model.
- the autoimmune demyelinating disease targeted by the preventive / therapeutic agent of the present invention includes various diseases. Roughly speaking, the disease is classified into diseases in which demyelination occurs in the central nervous system and diseases in which demyelination occurs in the peripheral nerve. Preferably, a disease in which a demyelinating condition occurs in the central nervous system is an object of the present invention.
- Acute sporadic encephalomyelitis includes idiopathic acute sporadic encephalomyelitis, viral infectious acute sporadic encephalomyelitis or acute sporadic encephalomyelitis after vaccination.
- Multiple sclerosis includes concentric sclerosis or neuromyelitis optica (Devic disease). These diseases, particularly multiple sclerosis, repeatedly remit and recur, but are the subject of the present invention at any time as a prophylactic agent during remission and as a therapeutic agent during relapse.
- Acute inflammatory demyelinating polyradiculitis includes Gui 11 ain-Barrre syndrome and the like.
- substances that suppress apoptosis suppress the apoptosis that occurs in each disease and bring about a therapeutic effect on the disease.
- substances that suppress apoptosis suppress apoptosis that is occurring or is occurring in each situation, and prevent disease. Bring effect.
- the prevention of the preventive / therapeutic agent of the present invention includes prevention in preventing a disease from occurring for the first time, and prevention of recurrence when the disease relapses after remission.
- mammals other than humans may be included.
- the substance that suppresses apoptosis used in the present invention is not particularly limited as long as it suppresses or inhibits apoptosis.
- a substance that inhibits the binding of a Fs-angs gonist or a Fass-Fas ligand are not particularly limited as long as they block signal generation or transmission by Fas at any stage and suppress the function or biological action (particularly apoptosis) of the Fas / Fas ligand system.
- a substance that suppresses the action, function, or expression of as ligand or Fa a substance that interacts with the extracellular domain of the Fas ligand or an extracellular domain of Fas, or that suppresses the interaction between the Fas ligand and Fas Influences the interaction between the intracellular region of the Fas cell and the intracellular factor interacting with it, or suppresses the activity of intracellular factors (eg, ICE-like protease) involved in the signaling of apoptosis via Fas. And those having various mechanisms of action. Also, it includes both proteinaceous high molecular substances and low molecular weight compounds.
- a Fas derivative, an anti-Fas antibody, an anti-Fas ligand antibody, an antisense oligonucleotide against the Fas or Fas ligand gene which has an activity of suppressing Fas-mediated apoptosis, Or an antisense oligonucleotide to the mRNA of the Fas ligand, Substances that interact with the intracellular region or ICE inhibitors.
- a Fas derivative, an anti-Fas antibody, or an anti-Fas ligand antibody which has an action to suppress apo1 ⁇ -cis through Fas, is used. preferable.
- the anti-Fas antibody or anti-Fas ligand antibody is preferably an antibody having an antigen of Fas or Fas ligand derived from the subject to be treated.
- an antibody using a human-derived Fas or Fas ligand as an antigen that is, an anti-human Fas antibody or an anti-human Fas ligand antibody is preferable.
- the anti-Fas ligand antibody is preferably a chimeric antibody or a humanized antibody.
- Chimeric antibodies are preferably, for example, chimeric antibodies comprising a constant region from a human antibody and a variable region from a non-human antibody for human therapy.
- the constant and framework regions (FR) are of human origin and the complementarity determining regions (CDR) are of non-human origin.
- FR constant and framework regions
- CDR complementarity determining regions
- a reshaped human antibody human antibody
- This is the result of replacing the complementarity-determining regions (CDRs) of a non-human mammal, such as a mouse antibody, with the complementarity-determining regions of a human antibody.
- Non-human antibodies can have biological disadvantages when used in human therapy, including relatively short circulating half-lives, lacking important immunoglobulin functional properties or being immunogenic.
- monoclonal antibodies with antigenicity to humans of various mice or other organisms will be developed, after several initial or initial treatments with any of the different non-human antibodies, Even treatment for subsequent unrelated therapies may be ineffective due to cross-reactivity or may themselves be dangerous substances.
- Chimeric or humanized antibodies overcome these.
- the Fas gonist used in the present invention is preferably one that suppresses apoptosis of Fas-expressing cells by an appropriate Atsey method described in W095Z13293 or the like. This specification refers to this gazette and is incorporated herein by reference.
- the antibody used in the present invention may be a polyclonal antibody or a monoclonal antibody, and the molecular species of the antibody used in the present invention is not particularly limited. As long as it binds to an antigen and inhibits apoptosis via Fas, it may be a normal form of an antibody molecule or a fragment of an antibody. For example, Fab, F (ab ') 2 , Fv, or a single-chain Fv (SCFv) in which the Fv of the H chain and the L chain are linked by an appropriate linker so as to form a single chain may be used. Can be.
- the anti-Fas ligand antibody or anti-Fas antibody used in the present invention can be prepared using known techniques.
- the preparation method is described in International Patent Application Publication Nos. WO 95Z13293 and WO95Z02290. This specification refers to this gazette and is incorporated herein by reference.
- the chimeric antibody that can be used in the present invention can be produced by using a known method for producing a chimeric body.
- a method for producing a chimeric protein is described in Example 1 of International Patent Application Publication WO 95/13293. This document describes this gazette This is incorporated herein by reference.
- Humanized antibodies for use in the present invention are described in Nature, et al., Nature, 332, 3232, 1998, European Patent Publication No. 02 39400, Quen et al., Pro. USA, Vol. 86, No. 10029, 1989, International Patent Application Publication Nos.WO 90/07861, W 092/11018, Co., etc., Proc. Natl. USA, 88, 2869, 1991, Co, etc., Nature, 351, 501, 1991 and Co, J. Immunol., 148, 1149, 1992 Etc. can be used.
- the present description refers to this document, and is incorporated herein by reference.
- Preferable examples of the present invention include a humanized anti-Fas ligand antibody having a CDR of a mouse antibody F919-9-9-18 antibody disclosed in Examples of International Patent Application Publication WO 97/02290. Can be
- the Fas derivative used in the present invention is not particularly limited as long as it has at least an ability to bind to a Fas ligand or suppresses apoptosis caused by the Fas ligand.
- the known Fas amino acid sequence has any mutation such as deletion, substitution, or addition of one or more amino acids, and maintains the binding activity to the Fas ligand while maintaining the biological activity of the FasZFas ligand system, particularly It includes those that suppress apoptosis through Fas. Specific examples include Fas mutants, truncated form Fas, chimeric proteins, fusion proteins, or chemically modified ones.
- the origin of the Fas is not limited to animal species as long as it has the above-mentioned properties, but human origin is considered in consideration of antigenicity. It is preferred to use
- Human Fas-Fc (hFas_Fc), which is a chimeric protein of the Fc region of human immunoglobulin, and the like.
- the Fas derivative may be of any production method, and can be produced by a known sequence and a known gene recombination technique. For example, the preparation method is described in Example 1 of International Patent Application Publication No. WO 95/13293 and in Example of WO 97/42319. This specification refers to this gazette and is incorporated herein by reference.
- Fas derivatives having a deletion at the N-terminus of Fas are also preferable, and among these, in particular, as of March 14, 1996, Ichigo-san, Ichigi-cho, Tsukuba 1-chome, Ichigi-cho, Ibaraki, Japan Deposited with the Biotechnology Research Institute (Accession No. P-15514 and Accession No. P-151515), and transferred from the original deposit to the international deposit on March 6, 1997 (Accession No. FERM BP — 58 54 and accession number FE RM BP — 58 55) Fas derivative sh Fas (nd 29) encoded by plasmids (pMl 304 and pMl 317) contained in E.
- coli — F c and shF as ( nd29) -hinge discloses a known human Fas extracellular Fas cell in which the N-terminal amino acids 1 to 29 have been deleted. It is a derivative containing a region and has high activity and is a preferred example as an active ingredient of the agent for preventing or treating cirrhosis of the present invention.
- the present specification refers to this document, and is incorporated herein by reference.
- Fas derivatives used in the present invention can be prepared by a suitable Atsie method. It is found that the compound has a binding activity or an inhibitory activity on apoptosis via Fas.
- the antisense oligonucleotide against the Fas or Fas ligand gene or the antisense oligonucleotide against the mRNA of the Fas or Fas ligand used in the present invention suppresses the expression of Fas or the Fas ligand.
- the sequence is not limited. Examples thereof include antisense oligonucleotides of the Fs ligand disclosed in Example 20 of International Patent Application Publication No. WO95 / 13293. This specification refers to this gazette and is incorporated herein by reference.
- the preventive and therapeutic agent for autoimmune demyelinating disease of the present invention can be used as a therapeutic agent for patients with autoimmune demyelinating disease.
- it can be used as a preventive agent for autoimmune demyelinating disease in patients with systemic autoimmune disease or organ-specific autoimmune disease other than nervous system, virus infected or vaccinated, etc.
- it can be used as a relapse preventive agent at the time of remission for autoimmune demyelinating diseases, especially diseases that repeatedly repeat remission and relapse such as multiple sclerosis.
- the preventive / therapeutic agent for autoimmune demyelinating disease of the present invention is characterized by containing the above-mentioned substance for inhibiting apoptosis, and comprises at least one pharmaceutical carrier or medium, for example, sterile water, physiological saline, vegetable oil , Mineral oil, higher alcohols, higher fatty acids or harmless organic solvents, etc., as required, excipients, colorants, emulsifiers, suspending agents, surfactants, solubilizing agents, anti-adsorption agents, stabilizers , A preservative, an antioxidant, a buffer, a tonicity agent or a soothing agent, etc., in an appropriate combination to form a pharmaceutical composition kit. It can be administered orally or parenterally, such as intravenously, intracoronarily, subcutaneously, intramuscularly, transdermally, by inhalation, rectally or topically.
- sterile water for example, sterile water, physiological saline, vegetable oil , Mineral oil, higher alcohols,
- it can be administered parenterally, systemically or locally, rapidly or continuously.
- the dosage for humans varies depending on the condition, age, and administration method of the patient, but it is necessary to select an appropriate amount.
- an appropriate divided volume in the range of about 0.01 to 1.0 Omg ZKg. In this range, it is preferable to select an appropriate divided capacity in the range of about 0.01 to 10 OmgZKg.
- the use of the agent for preventing or treating an autoimmune demyelinating disease of the present invention is not limited to these administration methods or dosages.
- multiple appointments such as a Fs-angs gonist, a substance that suppresses the binding of a Fs-Fas ligand, or an anti-Fs ligand antibody. ⁇ It may be used in combination with a substance that controls one cis, or in combination with other drugs.
- an injectable preparation may be a purified substance that suppresses apoptosis, for example, a Fas antagonist, a substance that suppresses the binding of a Fas-Fas ligand, or an anti-Fas ligand antibody or a solvent such as saline or buffer. Dissolved in water and, if necessary, add an anti-adsorption agent to make a formulation. In addition, it may be lyophilized for reconstitution before use, or may be formulated by adding a general excipient for lyophilization.
- the apoptosis-suppressing substance used in the prophylactic / therapeutic agent for an autoimmune demyelinating disease of the present invention is used in an autoimmune demyelinating disease model, particularly in the central nervous system as shown in Examples.
- an autoimmune demyelinating disease model that causes the marrow, it shows an inhibitory effect on organ and tissue damage.
- the effects of suppressing the damage to organs and tissues shown in the Examples are preventive effects, therapeutic effects, and their combined effects.
- the effects can be shown by examining the disease in a relapse model.
- experiments were performed using a mouse model, and thus, an anti-mouse Fas ligand antibody was used to demonstrate the effect of suppressing organ and tissue damage. The same effect as in the example can be expected by the human Fas ligand antibody.
- the preventive / therapeutic agent for autoimmune demyelinating disease of the present invention has no toxicity as shown in the examples and can be used safely. That is, the preventive / therapeutic agent for autoimmune demyelinating disease of the present invention is expected to have a preventive, therapeutic or ameliorating effect on autoimmune demyelinating disease.
- the method for producing the anti-Fas ligand antibody, the humanized anti-Fas ligand antibody and the Fas derivative of the present invention and the apoptosis-suppressing activity are disclosed in Examples of International Patent Applications WO 97Z02290 and WO 97/42319. .
- Mouse Fas ligand extracellular region derived from soluble mouse Fs ligand WX 2 (J. Immunology, 157, 3918-3924, 1996)
- a gene encoding a chimeric protein fused to the mouse CD40 ligand intracellular domain, transmembrane domain and part of the extracellular domain (78 amino acids from the N-terminus) is located downstream of the Human Elongation Factor 1 (EF) Promoter Seven plasmids were prepared (Mizushi ma-Nagata, Nucl eic Acids Research, 18, 5322, 1990).
- the above plasmid was transfected into WR19L cells, and recombinant cells W40 LFL expressing mouse Fas ligand on the cell membrane were obtained and used as antigens for administration.
- Armenian hamsters were used as immunized animals.
- Freund's complete adjuvant and 1 X 10 7 cells of W40 LFL mixed administered subcutaneously Armenian hamsters, 2 X 1 0 7 amino W40 LFL suspended in PBS was administered subcutaneously after one month.
- 5 ⁇ 10 s W40 LFL suspended in PBS were administered to the footpad.
- the lymph node cells were removed and fused with mouse myeloma cells P3-X63-Ag8-U1 (P3-U1).
- the hybridoma FLIM After selection with HAT medium (hypoxanthine-aminopterin-thymidine), the hybridoma FLIM, which has the activity of neutralizing the cytotoxicity of mouse Fas ligand in the culture supernatant from the grown hybridomas I got 58.
- Hypridoma FL I M58 was cultured in serum-free medium, Hy bridoma-S FM (GI BCO BRL), and the culture supernatant was purified using a protein A column (PROS EP—A, Bioprocessing). Antibody FLIM 58 was obtained. The protein concentration was calculated from the absorbance at 280 nm.
- Example 2 Toxicity test of anti-mouse Fas ligand antibody FLI ⁇ LI58 (1) Method
- Anti-mouse F aS ligand antibody FLIM58 was administered via the tail vein at a dose of 100 mg Z3Om1 / kg.
- the control group received physiological saline at a dose of 3 Oml / kg via the tail vein.
- Each of the two strains had three cases per group.
- the observation period was set to 7 days, and body weight measurement, hematology (red blood cells, white blood cells, platelets), blood biochemical tests (GOT, GPT, urea nitrogen), and visual necropsy were performed.
- Body weight gain, hematological test values (red blood cells, white blood cells, platelets), and blood biochemical test values (GPTT, GPT, urea nitrogen) after administration of the FLIM 58-treated group No difference was found.
- no abnormalities were found in the group administered with the anti-mouse Fs ligand antibody FLIM58 by autopsy findings by visual inspection.
- Complete Freund's adjuvant (manufactured by Difco Laboratories) containing 1 mg Zm 1 of killed H37Ra tuberculosis (Difco Laboratories) 10 ml was centrifuged at 1,000 rpm for 5 minutes, and the resulting precipitate was treated with 1.6 ml Freund Incomplete adjuvant (Manufactured by Difco Laboratories) to produce a complete adjuvant having an increased concentration of killed H 37 Ra tuberculosis bacteria.
- Guinea pig brain-derived myelin basic protein (Sigma) was dissolved in physiological saline to a concentration of 2.5 mgZm 1, and the above-mentioned complete adjuvant with an increased concentration of H37Ra tuberculosis-killed bacteria was added to 1: 1.
- the mixture was mixed, and an emulsion was prepared using a Luer-lock type Hamilton gas evening syringe (manufactured by Chuo Chemical Industry).
- mice Female, 11-week-old, Lewis rats were anesthetized by intraperitoneal injection of 5 OmgZkg of pentobarbital (manufactured by Dainippon Pharmaceutical), and the above emulsion was applied to both hind limbs (Foot ad). 1 was administered respectively. Fourteen days later, the spleen was removed, loosened using tweezers, and centrifuged. The obtained cell precipitate was suspended in a 0.017M Tris-0.747% ammonium chloride solution, and only erythrocytes were hemolyzed. The remaining cells were washed with Hanks' solution (Nissui Pharmaceutical) to obtain spleen cells.
- Hanks' solution Nasui Pharmaceutical
- the disease state was scored based on the criteria shown in Table 1 below (Experimenta 1N eurology, 151, 221, pp. 22-228, 1995), and the effect of FLIM 58 administration was examined. .
- the results are shown in FIGS.
- the condition is d ay 5 to d ay 6 (days after transplantation 5 days to 6 days). The following day, the same shall apply hereinafter), and the disease state of the FLIM58-administered group was milder than that of the control group after day 6.
- Weight loss associated with the onset of the disease state occurred from d ay 4 to d ay 5, and after d ay 5, the weight loss of the FLIM58-administered group was milder than that of the control group.
- a 1: 1 emulsion of myelin basic protein and complete adjuvant was prepared in the same manner as in Example 3, and a 0.2 ml / Fot pad dose (0.2 mi rat) was administered to both feet of the rat under anesthesia.
- OmgZkg of the anti-mouse Fs ligand antibody FLIM58 was administered via the tail vein 7 days after the splenocyte transplantation (day 7).
- the control group received an equal amount of purified IgG derived from normal hamster monoglobulin. There were 5 cases in each group.
- the disease state was scored based on the criteria in the table shown in Example 3, and the administration effect of FLIM58 was examined.
- the therapeutic agent for preventing or treating autoimmune demyelinating diseases of the present invention which comprises a substance that inhibits apoptosis as an active ingredient, has an inhibitory effect on apoptosis, and particularly, Fas / represented by Fas-mediated cell death. It has a prophylactic or therapeutic effect on autoimmune demyelinating diseases involving apoptosis such as the biological action of the Fas ligand system. Therefore, the substance that suppresses apoptosis of the present invention is expected as a prophylactic / therapeutic agent for autoimmune demyelinating diseases in which apoptosis is involved, such as death of cells mediated by Fas.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002333880A CA2333880A1 (en) | 1998-05-29 | 1999-05-28 | Preventives/remedies for autoimmune demyelinating diseases |
DE69932434T DE69932434D1 (de) | 1998-05-29 | 1999-05-28 | Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten |
EP99922536A EP1082967B1 (en) | 1998-05-29 | 1999-05-28 | Prevention and treatment of autoimmune demyelinating diseases by Fas-antagonists |
US09/701,486 US6759041B1 (en) | 1998-05-29 | 1999-05-28 | Preventives/remedies for autoimmune demyelinating diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14953098 | 1998-05-29 | ||
JP10/149530 | 1998-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999062554A1 true WO1999062554A1 (fr) | 1999-12-09 |
Family
ID=15477161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/002818 WO1999062554A1 (fr) | 1998-05-29 | 1999-05-28 | Preparations de prevention / de traitement de maladies demyelinisantes auto-immunes |
Country Status (6)
Country | Link |
---|---|
US (1) | US6759041B1 (ja) |
EP (1) | EP1082967B1 (ja) |
AT (1) | ATE333287T1 (ja) |
CA (1) | CA2333880A1 (ja) |
DE (1) | DE69932434D1 (ja) |
WO (1) | WO1999062554A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516362A (ja) * | 1999-12-07 | 2003-05-13 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | 薬物におけるTNF−αおよびCD95Lの生物学的効果を阻害する化合物の組合せ |
JP2010512403A (ja) * | 2006-12-11 | 2010-04-22 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 炎症の治療法としてのαBクリスタリン |
US8771689B2 (en) | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7848848B2 (en) * | 2006-04-28 | 2010-12-07 | Freeslate, Inc. | Robotic station for capturing both image and weight of a sample |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63230629A (ja) * | 1987-03-19 | 1988-09-27 | Microbial Chem Res Found | 自己免疫疾患予防治療剤 |
WO1998010070A1 (fr) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas |
WO1998018487A1 (fr) * | 1996-10-31 | 1998-05-07 | Mochida Pharmaceutical Co., Ltd. | Agent prophylactique/therapeutique |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620889A (en) * | 1993-10-14 | 1997-04-15 | Immunex Corporation | Human anti-Fas IgG1 monoclonal antibodies |
US5830469A (en) * | 1993-10-14 | 1998-11-03 | Immunex Corporation | Fas antagonists and uses thereof |
JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
IL114615A0 (en) | 1995-07-16 | 1995-11-27 | Yeda Res & Dev | Modulators of the function of fas receptors and other proteins |
JP3925663B2 (ja) | 1995-06-30 | 2007-06-06 | 持田製薬株式会社 | 抗Fasリガンド抗体および該抗体を用いた測定法 |
US6399327B1 (en) * | 1995-07-16 | 2002-06-04 | Yeda Research And Development Co. Ltd. | Modulators of the function of FAS receptors and other proteins |
US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
EP0965637B1 (en) | 1996-05-02 | 2005-07-20 | Mochida Pharmaceutical Co., Ltd. | Fas ANTIGEN DERIVATIVES |
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US6358508B1 (en) * | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
KR100580333B1 (ko) | 1997-10-10 | 2006-05-16 | 시토비아 인크. | 디펩티드 고사 억제제 및 그의 용도 |
US6184210B1 (en) * | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
US6098631A (en) * | 1998-01-21 | 2000-08-08 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disease |
-
1999
- 1999-05-28 EP EP99922536A patent/EP1082967B1/en not_active Expired - Lifetime
- 1999-05-28 CA CA002333880A patent/CA2333880A1/en not_active Abandoned
- 1999-05-28 WO PCT/JP1999/002818 patent/WO1999062554A1/ja active IP Right Grant
- 1999-05-28 US US09/701,486 patent/US6759041B1/en not_active Expired - Fee Related
- 1999-05-28 DE DE69932434T patent/DE69932434D1/de not_active Expired - Lifetime
- 1999-05-28 AT AT99922536T patent/ATE333287T1/de not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63230629A (ja) * | 1987-03-19 | 1988-09-27 | Microbial Chem Res Found | 自己免疫疾患予防治療剤 |
WO1998010070A1 (fr) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas |
WO1998018487A1 (fr) * | 1996-10-31 | 1998-05-07 | Mochida Pharmaceutical Co., Ltd. | Agent prophylactique/therapeutique |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516362A (ja) * | 1999-12-07 | 2003-05-13 | ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ | 薬物におけるTNF−αおよびCD95Lの生物学的効果を阻害する化合物の組合せ |
JP2010512403A (ja) * | 2006-12-11 | 2010-04-22 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 炎症の治療法としてのαBクリスタリン |
US8771689B2 (en) | 2006-12-11 | 2014-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for ischemia or inflammation |
US8835391B2 (en) | 2006-12-11 | 2014-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | Alpha B-crystallin as a therapy for multiple sclerosis |
Also Published As
Publication number | Publication date |
---|---|
EP1082967B1 (en) | 2006-07-19 |
EP1082967A1 (en) | 2001-03-14 |
EP1082967A4 (en) | 2001-11-07 |
ATE333287T1 (de) | 2006-08-15 |
CA2333880A1 (en) | 1999-12-09 |
DE69932434D1 (de) | 2006-08-31 |
US6759041B1 (en) | 2004-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100520339B1 (ko) | 면역조절 방법 및 조성물 | |
ES2247638T3 (es) | Uso de anticuerpos contra el antigeno leucociterio cd45ro para inmunomodulacion. | |
US11608377B2 (en) | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist | |
CN110179989B (zh) | 治疗狼疮的方法和组合物 | |
US7923010B2 (en) | Methods and materials for treating autoimmune diseases and conditions | |
US20060251646A1 (en) | Anti-tirc7 antibodies in therapy of inflammatiory diseases | |
CN1261285A (zh) | 治疗性蛋白抑制剂综合症的cd154阻断治疗 | |
JP4339405B2 (ja) | 予防・治療剤 | |
CA2621248A1 (en) | Anti-human sr-b1 antibody reducing inflammation and treating auto-immunedisease | |
US20200376118A1 (en) | A B Cell Depleting Agent for the Treatment of Atherosclerosis | |
WO1999062554A1 (fr) | Preparations de prevention / de traitement de maladies demyelinisantes auto-immunes | |
WO1999039737A1 (fr) | Medicaments pour prevenir/traiter la maladie intestinale inflammatoire | |
WO1999037328A1 (fr) | Composes destines a la prevention/au traitement du sida | |
KR20230142834A (ko) | 항-cd38 항체 및 이의 용도 | |
JPH11335299A (ja) | 抗癌剤または放射線療法の副作用軽減剤 | |
CN116854819A (zh) | 抗cd25抗体及其应用 | |
EP4164745A1 (en) | Use of cxcl13 binding molecules to promote peripheral nerve regeneration | |
EP1077069B1 (en) | Preventives/remedies for hepatic cirrhosis | |
CN113874034A (zh) | 脑缺血再灌注损伤的治疗 | |
WO2020018364A1 (en) | Anti-galectin-9 antibody and methods of use thereof | |
IL190101A (en) | Anti-sr – b1 antibodies and preparations containing them for the diagnosis and treatment of inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2333880 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999922536 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09701486 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999922536 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999922536 Country of ref document: EP |